Miami, FL: Two antitrust class action lawsuits have been filed against Shire US Inc, the manufacturer of the ADHD drug Adderall XR, alleging the pharmaceutical company stifled competition in order to monopolize the market and/or restrict trade in an effort to increase profits.
The lawsuits, filed in Pennsylvania and Florida, are Netwall v. Shire U.S., Inc. et al., Case No. 13-cv-01669, U.S. District Court for the Eastern District of Pennsylvania, and Barba et al v. Shire US, Inc. et al, Case No. 13-cv-21158, U.S. District Court for the Southern District of Florida.
The Florida antitrust class action lawsuit states, "Though other companies were able to bring an Authorized Generic to the market in 2009, Defendants engaged in a number of schemes meant to delay the entry of . and then to restrict the supply of generic competition."And, "Namely, Defendants filed sham patent litigation, constructed anticompetitive reverse payment agreements with generic competitors, and even then proceeded to breach agreements to supply said competitors with materials to manufacture generic AXR, cutting off supply of cheaper-priced generic AXR to consumers."
Plaintiffs in the lawsuits also content that the "pay-for-delay"settlements reached in the patents litigation were part of a larger plan to delay the entry of generic competition and to restrict competitors by failing to supply them with as much of its authorized generic Adderall as promised under the supply agreements.
The two antitrust class action lawsuits are brought on behalf of all persons in Pennsylvania, Florida and the US, who purchased brand name Adderall XR for personal use and not for resale.
